The ultimate goal is to identify and target modifiable risk factors that will reduce major cardiovascular events in African American lupus patients. As a first step toward achieving this goal, this study was designed to explore risk factor models of preclinical atherosclerosis in a predominantly African American group of patients with systemic lupus erythematosus (SLE) using variables historically associated with endothelial function in nonlupus populations. Fifty-one subjects with SLE but without a history of clinical cardiovascular events were enrolled. At entry, a Framingham risk factor history and medication list were recorded. Sera and plasma samples were analyzed for lipids, lupus activity markers and total 25-hydroxyvitamin D (25 OH)D) levels. Carotid ultrasound measurements were performed to determine total plaque area (TPA) in both carotids. Cases had TPA values above age-matched controls from a vascular prevention clinic population. Logistic regression and machine learning analyses were performed to create predictive models. 25(OH)D levels were significantly lower, and SLE disease duration was significantly higher in cases. 25(OH)D levels inversely correlated with age-adjusted TPA. Angiotensin-converting enzyme (ACE) inhibitor nonuse associated with case status. Logistic regression models containing ACE inhibitor use, 25(OH)D levels and low-density lipoprotein levels had a diagnostic accuracy of 84% for predicting accelerated atherosclerosis. Similar results were obtained with machine learning models, but hydroxychloroquine use associated with controls in these models. This is the first study to demonstrate an association between atherosclerotic burden and 25(OH)D insufficiency or ACE inhibitor nonuse in lupus patients. These findings provide strong rationale for the study of ACE inhibitors and vitamin D replenishment as preventive therapies in this high-risk population.
S
ystemic lupus erythematosus (SLE) is an independent risk factor for atherosclerosis and major adverse cardiovascular events (MACE). 1 African American lupus patients have an earlier onset of cardiovascular disease (CVD) hospital admission and tend to have earlier in-hospital deaths from CVD than their white lupus counterparts. 2 The mechanisms behind this racial disparity are not known. The standard Framingham risk model for CVD is not predictive in lupus patients, engendering the hypothesis that there are independent mechanisms driving accelerated atherosclerosis in this patient population. 1 Several independent mechanisms may result in accelerated CVD in patients with SLE. The mechanisms proposed to date can ultimately lead to endothelial dysfunction, a functional characteristic common to SLE subjects with atherosclerosis 3 that is an independent risk factor for MACE in the general population and in patients with SLE. 4 Because of the heterogeneity of the lupus phenotype, it is expected that no single marker will be effective in predicting CVD and ultimately MACE in patients with SLE. We hypothesized that low vitamin D levels would associate with atherosclerosis for the following reasons: (1) low 25(OH)D levels are associated with MACE in nonlupus populations, 5 (2) repletion of 25(OH)D in vitamin D-deficient non-lupus patients improved vascular endothelial function, 6 and (3) African American lupus patients have a high prevalence of vitamin D deficiency. 7 We further hypothesized that angiotensin-converting enzyme (ACE) inhibitor use would associate with lower levels of atherosclerosis because of literature supporting a role for ACE inhibitors in improving endothelial function. 8 Therefore, we hypothesized that multiple traditional and novel markers that are surrogates for mechanisms of endothelial cell dysfunction can be used to create a model of atherosclerosis in a largely African American patient population with SLE. Such models might support a role for the study of non-Framingham risk factors that can be modified to improve endothelial function in this population.
MATERIALS AND METHODS

Study Design
The goal of this study was to determine risk factor models for accelerated early atherosclerosis in a largely African American population of lupus patients. This is a cross-sectional within-lupus case-control pilot study to evaluate novel and traditional risk factors for accelerated atherosclerosis in a largely African American SLE population. The variables considered as risk factors and covariables for the early atherosclerosis outcome were age, traditional Framingham risk factors for atherosclerosis, measures of SLE disease activity and damage, serum 25-hydroxy vitamin D (25(OH)D) levels and immunosuppressive, renin-angiotensin acting antihypertensive, statin and total calculated corticosteroid medication use. Participants were considered to have accelerated atherosclerosis (cases) if their age-adjusted carotid total plaque area (TPA) was greater than the mean of historical controls in a vascular prevention clinic. The historical control population in this study was used to reduce the confounding effect of age on TPA rather than to directly compare TPA in SLE and non-SLE populations.
SLE Participant Inclusion Criteria
Participants met at least 4 of the 1997 revised American College of Rheumatology SLE criteria. 9 All procedures performed were approved by the Medical University of South Carolina institutional review board, and all subjects gave informed consent before initiation of any study-related procedures.
SLE Participant Exclusion Criteria
Because the goal was to determine markers of subclin-ical atherosclerosis, participants with a history of CVD end-points such as myocardial infarction (MI), stroke (cerebrovascular accident), or documented peripheral, coronary, or carotid artery functionally significant narrowing were not included in the study.
Plaque Area Determination
Carotid TPA was chosen as a surrogate for cardiovascular outcomes in this study for several reasons. First, TPA allows one to see differences between groups with far fewer subjects than intima media thickness, 10 and baseline TPA measures associate with hard cardiovascular endpoints such as 5-year risk for stroke, MI and vascular death. 11 When compared directly with intima media thickness in prospective, longitudinal study, TPA was superior in predicting MI. 12 TPA was also more predictive of MI in women than in men, which is ideal for studying lupus populations. 13 Lupus subjects have a higher prevalence of carotid plaque than nonlupus controls, making a plaque measure more relevant for a lupus population than intima-media thickness.
14 Measuring the size of plaque burden (a continuous variable) rather than measuring the presence of plaque (an ordinal variable) enhances the statistical power of the TPA measure, allowing us to reduce the sample size for this study. Finally, TPA can be age adjusted from an historical population.
11
TPA was measured using a Phillips iU22 Ultrasound system and a L9-3 9 mHz probe in 2D mode by a single operator at each center (Charleston and London). The Charleston operator was trained by, and proper techniques were confirmed by the London operator. TPA measurements were performed as previously reported. 11 As a quality control measure, 10 participants were randomly selected from a convenience population of volunteers in Charleston for repeated measures within a month. The intraoperator repeated measures intraclass correlation coefficient was 0.96 [95% confidence interval (CI) 0.84-0.99], whereas the weighted kappa statistic was 0.950 (95% CI, 0.88-1.00), for the Charleston operator; the reliability of the London, Ontario, operator was equivalent and was described previously. 10 Control Population for Age Adjustment of TPA The age adjustment controls were 4,272 patients recruited from the Premature Atherosclerosis Clinic and the Stroke Prevention Clinic of the University Campus of the London Health Sciences Centre (London, Ontario) (Spence JD, written communication, 2010). Participants, described previously, 15 were referred to the clinic for premature atherosclerosis, stroke, transient ischemic attack, or asymptomatic narrowing of the carotid artery. These controls were used to adjust TPA values for age in the diagnostic models. The Charleston quality control population was also used to confirm similar TPA values between the Charleston, South Carolina, and London, Ontario, controls. Because lupus disease activity may contribute to the development of atherosclerosis in this population, we categorized disease activity by using the SELENA-SLEDAI index. 16 Because SLE and medication-related damage may be a surrogate for cardiovascular risk factors, the SLICC/ACR Damage Index was used to quantify this damage. 17 
Determination of Traditional Cardiovascular Risk Factors
Traditional risk factors for atherosclerosis were assessed. Historical risk factors determined by interview and chart review were a first-degree relative with history of stroke, MI, or accelerated onset of MACE (earlier than age 50 in men and age 55 in women), history of major cardiovascular event or peripheral vascular disease, sex, number of years since SLE diagnosis, history of hypertension, diabetes, obesity, hypercholesterolemia (HC), end-stage renal disease or smoking (past or present, reported as pack*years). The following risk factors were determined at visit 1: systolic blood pressure (SBP), diastolic blood pressure, height, weight, body mass index and waist-to-hip ratio. Medication histories were performed by interview and chart review. The following medications were recorded as either present or absent: immu-nosuppressants (mycophenolate mofetil, mycophenolic acid, azathioprine or methotrexate), hydroxychloroquine, ACE, angio-tensin receptor blockers and statins.
Standard Laboratory Assessments
The Medical University of South Carolina Special Chemistry and Immunology Laboratories performed the following: urine creatinine, protein, and cell count and serum C3, C4, anti-double stranded DNA antibody levels (dsDNA), complete blood count, complete metabolic panel and plasma very low-density lipoprotein, low-density lipoprotein (LDL), high-density lipoprotein, triglycerides and total cholesterol. Renal function [estimated glomerular filtration rate (eGFR)] was calculated by the abbreviated 4 variable Modified Diet in Renal Disease equation. If the eGFR was calculated to be .60, then the Cockroft-Gault equation was used. 18 
Serum Total 25(OH)D and Parathyroid Hormone Analysis
Serum 25(OH)D levels were determined using a nonchromatographic radioimmunoassay as previously described. 19 Serum parathyroid hormone (PTH) levels were determined using an immunoradiometric assay (DiaSorin, Stillwater, MN). The laboratory participates in the international Vitamin D External Quality Assessment Scheme.
Determination of Total Prednisone Exposure
Total accumulated prednisone dose was calculated by interview and chart review and reported in grams of prednisone glucocorticoid equivalent. Accumulated exposure between clinic visits was considered to be constant unless a taper was prescribed.
Data Collection and Management
Study data were collected and managed using REDCap (Research Electronic Data Capture, REDCap Project), a secure, web-based application designed to support electronic data capture for research studies.
Statistical Analysis
The distribution of variables was determined using Kolmogorov-Smirnov and Shapiro-Wilk tests. Comparisons between groups were made using Student t test or Mann-Whitney U test according to the distribution of the data. For crosstab associations, a x 2 was performed, with Fisher's exact test used when appropriate. For nonparametric receiver operating characteristics (ROC) analysis, continuous variables were tested against case status and reported as the area under the ROC curve (AUC) with 95% CI. The state variable was the case state unless a putative "protective" variable was tested. Correlations were determined using Pearson or Spearman correlation according to the distribution of the data. Backward, stepwise, logistic regression was performed using categorical and continuous variables that were significant (P # 0.1) in correlation or x 2 analyses with the exception of disease activity parameters, which are not expected to impact TPA given the waxing and waning nature of SLE disease activity. Season (March to September or October to February) was included as a variable in this analysis. The model with the greatest accuracy for predicting plaque state was reported along with the likelihood ratio (LR) and P value. Missing values (25(OH) vitamin D levels for 1 case and 1 control) were imputed as the means of cases and controls. P values #0.05 were considered significant. Statistical analysis was performed using PASW Statistics vl8.0 (SPSS, Chicago, IL).
Nonlinear Modeling
Machine learning was used to explore variables that may be important in predicting atherosclerosis and to determine whether nonlinear algorithms could produce models with greater diagnostic power than conventional linear models. Nearest Related Neighbor (NRN) modeling is an experimental supervised machine learning technique for multivariable analysis that uses a nonparametric support vector machine to segregate cases and controls based on the variable characteristics of neighboring cases and controls. 20 Input variables were chosen based on historical precedent (Framingham risk factors and variables associated with either increased or decreased endothelial function) or performance in bivariate or logistic regression analysis described above. NRN was performed using an algorithm created in MatLab (The Mathworks, Natick, MA) by Almeida. 21 Variables that produced the most predictive model (ie, fewest wrong neighbors were identified) and the ROC AUC for the model were reported. A feed-forward artificial neural network (ANN) machine learning algorithm created in MatLab by Almeida was used to create a predictive model of abnormal TPA as described. 22 This type of algorithm, unlike traditional linear regression, can create predictive models from large numbers of input variables. This algorithm can still perform well if there is colinearity between input variables or if associations between inputs and outputs are nonlinear. 23 The same input variables were used in the ANN analysis. Eleven ANNs were trained, and the ROC AUC of the median model was reported. The input variables with the greatest relative importance (sensitivity) in predicting abnormal TPA in this median model were reported. (Table 1) , although the mean for each group was below sufficient levels. 24 Of note, all subjects with 25(OH)D levels of .30.3 ng/mL had normal PTH levels, whereas 29% of those with lower levels had increased PTH levels (data not shown). This suggests that 25(OH)D levels required to suppress PTH in other populations apply to this largely African American population as well. Renal function was similar between cases and controls (Table 1) , and renal function did not correlate with 25(OH)D in this population (r 5 0.01, P 5 0.9). Framingham risk factors were not significantly different in the cases compared with the controls (Table, Supplemental Digital Content 2, http://links.lww.com/MAJ/A5). LDL levels tended to be higher in those with increased TPA, but the differences did not reach statistical significance (P 5 0.07). Several lupus-related factors were different between groups. Cases had FIGURE 1. Defining the lupus case population: age-adjusted carotid plaque area in lupus subjects compared with a vascular prevention clinic population. The distribution of carotid total plaque area (TPA in cm 2 ) by age in lupus patients (open triangles) compared with an historic population of stroke and hypertension prevention clinic patients (men, solid line; women, dashed line). TPA is presented on the y axis, whereas age is represented on the x axis. Note the lupus cases with TPA values above age-matched controls in the vascular prevention clinic. a longer SLE disease duration than controls but did not have different SLICC scores. Differences in age or the age of onset of lupus were not significant. Those with increased TPA had lower double-stranded DNA antibody levels and SLEDAI scores and greater complement levels.
Age and SLE Disease Duration Correlate With TPA, Whereas SLEDAI Elements and 25(OH)D Are Inversely Correlated With TPA
Correlations between traditional and SLE-related risk factors for CVD and TPA were determined. None of the traditional cardiovascular risk factors correlated with TPA except for age (r 5 0.58, P , 0.001). SBP was negatively associated with TPA (r 5 -0.30, P 5 0.035). This is not entirely unexpected because TPA in other studies is a more effective marker of risk for cardiovascular outcomes than hypertension. 25 TPA was positively associated with the number of years since SLE diagnosis (r 5 0.37, P 5 0.008) and SLE onset age (r 5 0.38, P 5 0.006). SLE activity measures were inversely associated with TPA (SLEDAI score, r 5 -0.31, P 5 0.03; C4, r 5 0.32, P 5 0.02). The number of years since SLE diagnosis was inversely associated with SLEDAI score (r 5 -0.48, P , 0.001), suggesting that the inverse association between SLEDAI score and TPA may relate to lower disease activity later in disease. Cumulative damage as measured by the total SLICC score or eGFR did not correlate with TPA when corrected for age. This observation suggests that patients with SLE in this population need not have severe major organ involvement or renal damage to develop premature atherosclerosis. To eliminate age as a factor in the analysis, TPA was expressed as an absolute area above the mean in age-matched control subjects. The same associations were observed in this analysis (data not shown), but when age was adjusted for in this manner, an inverse correlation between 25(OH)D was observed (r 5 -0.33, P 5 0.018).
ACE Inhibitor Nonuse and High LDL Associate With High TPA
By x 2 analysis, those subjects who were not taking an ACE inhibitor were much more likely to have increased TPA (LR 5 9.0, P 5 0.02). No subjects taking an ACE inhibitor (n 5 12) had an increased TPA, whereas 14 of the 39 patients not taking an ACE inhibitor had an increased TPA. Associations between ACE inhibitor use and other potential cardiovascular risk factors were described to explore for potential confounding variables. All subjects taking an ACE inhibitor had a history of hypertension; however, those with a history of hypertension were not more or less likely to have an increased TPA. Similarly, those with an increased TPA did not have significantly greater amounts of proteinuria. Renal function was similar between ACE inhibitor users and nonusers (78 611 versus 88 6 6, P 5 0.4). These combined observations suggested that ACE inhibitor use was not simply a marker for hypertension or renal disease. Those with current or previous HC were also more likely to have increased TPA (LR 5 3.9, P 5 0.048), and baseline LDL .100 was also a risk factor for increased TPA (LR 5 4.6, P 5 0.032). Those with 25(OH) D levels ,15 ng/mL tended to be cases (LR 5 3.8, P 5 0.051).
25(OH)D and SLE Disease Activity Elements Discriminate Between Normal and Abnormal TPA
To explore the combined sensitivity and specificity of individual risk factors in predicting increased TPA, ROC curves were created for all continuous variables against the diagnosis of increased TPA. Subject 25(OH)D level at entry resulted in a significant ROC AUC (0.71; CI 0.52-0.89; P 5 0.03) for increased TPA. None of the traditional cardiovascular risk factors resulted in ROC AUC values that were significant. Of note, the lupus activity parameters associated with lack of plaque, whereas SLE disease duration associated with plaque [C4 level 0.70 (0.55-0.86), P 5 0.03; anti-dsDNA levels 0.70 (0.55-0.85), P 5 0.03; SLE duration 0.69 (0.54-0.84), P 5 0.04].
Logistic Regression Model Favors ACE Inhibitor Use, Low 25(OHD) and HC for Diagnosing Abnormal TPA A backward stepwise logistic regression analysis was performed using season, 25(OH)D level, entry LDL level, ACE inhibitor use and hydroxychloroquine use. Season and hydroxychloroquine use did not contribute significantly to the model and were excluded. The model with the best overall accuracy contained ACE inhibitor use, 25(OH)D levels and history of HC (x 2 5 15.9, P 5 0.001). The sensitivity for predicting abnormal TPA was 46%, whereas the specificity was 92%, and the overall diagnostic accuracy was 80% ( Table 2 ). The model LR was 16.6. A similar analysis using LDL at baseline instead of entry history of HC produced a similarly robust model (data not shown). Similar results were obtained when imputed variables (25(OH)D values for 1 case and 1 control) were excluded from the analysis or when season was included in the model (data not shown).
NRN Models Containing Hydroxychloroquine, ACE Inhibitor and Statin Use and 25(OH)D Levels Are Most Diagnostic of Abnormal TPA
Input variables for NRN modeling were chosen either because they were significant in ROC analysis (AUC .0.6) or because they were associated with CVD in other studies. Season Table 2) .
ANN Models Use Multiple Traditional and Novel Variables to Create a Model With Excellent
Diagnostic Power ANN analysis is well suited for large numbers of input variables with large datasets. Nonlinear and colinear associations can be included in ANN models. 23 The median performing exploratory model was selected after training 11 ANN models. The median ROC AUC was 0.88. Waist-to-hip ratio, body mass index, SBP, hydroxychloroquine use, triglyceride level, 25(OH)D level, SLE onset age, diastolic blood pressure, LDL, age, SLEDAI score, ACE inhibitor use, season, diagnosis of HC, SLICC score and years with SLE diagnosis accounted for (in that order) 89% of the sensitivity in the model (Table 2 ).
DISCUSSION
The current study was designed to determine potentially modifiable clinical risk factors that associate with atherosclerosis in a predominantly African American cohort of patients with SLE. In this study, ACE inhibitor and hydroxychloroquine nonuse, HC, and lower 25(OH)D levels were modifiable factors significantly associated with increased TPA.
To our knowledge, this is the first study to demonstrate an association between ACE inhibitor nonuse and abnormal atherosclerotic plaque in SLE. A possible protective effect of this medication is consistent with lower rates of atherosclerosis and cardiovascular events among ACE inhibitor users in non-SLE at-risk populations. 26 ACE inhibitors may work through restoration of endothelial cell function. 8 The mechanism behind this effect is not fully understood. However, ACE inhibitors lead to improved endothelial function in patients with vascular disease. 8 Angiotensin receptor I ligation leads to superoxide generation that reduces nitric oxide levels and thus endothelial function. ACE inhibitors may also work by inhibiting these processes. 27 These hypotheses are not addressed in the current study but provide rationale for future investigation.
To our knowledge, this is also the first study to demonstrate a significant association between 25(OH)D deficiency and abnormal atherosclerotic plaque in patients with SLE. Wu et al 28 reported an association between 25(OH)D and cardiovascular risk factors but did not show an association with imaging markers of atherosclerosis. The current study may have reached significance in a smaller number of patients because of a greater prevalence of 25(OH)D deficiency in our study population (61% with levels ,15 ng/mL versus 20% in the cohort described by Wu et al), and studies using TPA as an endpoint require fewer numbers of subjects. In a similar study by Mok et al, 29 low 25(OH)D levels were associated with cardiovascular risk factors such as dyslipidemia but not with abnormal intima media thickness or coronary calcium. A lack of association in the Mok study may have occurred because there was no normalization for age or measurement of a plaque area in the atherosclerosis imaging. A possible protective effect of 25(OH)D suggested by the current study is consistent with other studies of non-SLE at-risk populations. Men in the Health Professionals Follow-up Study with deficient 25(OH)D levels ( #15 ng/mL) at baseline had greater adjusted risk of MI after 10 years than those with sufficient levels ($30 ng/mL). 5 In another prospective, longitudinal study, successful supplementation of deficient 25(OH)D levels (to .30 ng/mL) was associated with reduced risk of coronary artery disease, MI, heart failure, stroke, renal failure and death. 30 The mechanisms through which vitamin D may prevent atherosclerosis in SLE are not known. However, the 1,25(OH)D/ vitamin D receptor complex can increase the expression of vascular endothelial growth factor (VEGF) in vascular smooth muscle cells. VEGF, in turn, increases endothelial nitric oxide synthase activity in endothelial cells and increases the number of endothelial progenitor cells responsible for repair of the endothelium. 31 The increased power of machine learning models to diagnose those with abnormal plaque demonstrates their utility in a multifactorial disease such as atherosclerosis on the setting of a heterogeneous disease such as SLE. These results provide the rationale for testing machine learning modeling in larger patient populations to validate this approach. This study is limited by its cross-sectional design and limited sample size. The sample size limitation is less concerning given the greater discriminatory power of TPA compared with traditional measures such as intima media thickness. 11 The findings of this study should be confirmed in longitudinal studies, and modeling should be qualified in an independent, external patient population. This study is unique in its focus on African American SLE subjects. 14 This study of a predominantly African American population of patients with SLE demonstrates an association between lower atherosclerotic burden and factors that are known to restore endothelial function in non-SLE populations or that reduce flare rates in SLE. This study provides a new rational basis for testing the effect of ACE inhibitors and/or 25 (OH)D repletion as primary atherosclerosis prevention in SLE.
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